Literature DB >> 19155945

Sudden fetal death in intrahepatic cholestasis of pregnancy.

Richard H Lee1, Marc H Incerpi, David A Miller, Bhuvan Pathak, T Murphy Goodwin.   

Abstract

BACKGROUND: Intrahepatic cholestasis of pregnancy is associated with an increased risk of fetal death. The mechanism of death is unknown. CASES: The first case involved a young primipara with pruritus and a bile acid concentration of 79 mumol/dL. While undergoing fetal heart rate monitoring, the fetus had a prolonged deceleration resulting in intrauterine death. The second case involved a young multipara with cholestasis who received ursodeoxycholic acid. Her bile acid concentration improved to13 micromol/dL. At 34 weeks of gestation, she had uterine contractions with prolonged decelerations resulting in delivery of her fetus with Apgar scores of 0, 0, and 5 at 1, 5, and 10 minutes, respectively.
CONCLUSION: Fetal death from intrahepatic cholestasis of pregnancy can be abrupt and not reliably predicted by the characteristics of the fetal heart rate tracing.

Entities:  

Mesh:

Year:  2009        PMID: 19155945     DOI: 10.1097/AOG.0b013e31818db1c9

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  11 in total

1.  Operative delivery rates following induction of labour for obstetric cholestasis.

Authors:  Jessica R Webster; Lucy Chappell; Floria Cheng; Andrew C G Breeze; Nuala Lucas; Felicity Plaat; Catherine Williamson
Journal:  Obstet Med       Date:  2011-05-24

2.  The impact of intrahepatic cholestasis of pregnancy on fetal cardiac and peripheral circulation.

Authors:  Seçil Kurtulmuş; Esra Bahar Gür; Deniz Öztekin; Ebru Şahin Güleç; Duygu Okyay; İbrahim Gülhan
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-06-01

3.  Bile acids in a multicenter, population-based case-control study of stillbirth.

Authors:  Robert M Silver; Corette B Parker; Robert Goldenberg; Uma M Reddy; Donald J Dudley; George R Saade; Carol J Rowland Hogue; Donald Coustan; Michael W Varner; Matthew A Koch; Deborah Conway; Radek Bukowski; Halit Pinar; Barbara Stoll; Janet Moore; Marian Willinger
Journal:  Am J Obstet Gynecol       Date:  2013-11-08       Impact factor: 8.661

4.  Intrahepatic cholestasis of pregnancy: biochemical predictors of adverse perinatal outcomes.

Authors:  Hui Chen; Yuan Zhou; Dong-Rui Deng; Hai-Yan Hao; Jing Dang; Jing Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-06-17

5.  Impaired fetal adrenal function in intrahepatic cholestasis of pregnancy.

Authors:  Chunfang Wang; Xiaojun Chen; Shu-Feng Zhou; Xiaotian Li
Journal:  Med Sci Monit       Date:  2011-05

6.  Comparative proteomics analysis of placenta from pregnant women with intrahepatic cholestasis of pregnancy.

Authors:  Ting Zhang; Yueshuai Guo; Xuejiang Guo; Tao Zhou; Daozhen Chen; Jingying Xiang; Zuomin Zhou
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

7.  The impact of intrahepatic cholestasis of pregnancy with hepatitis B virus infection on perinatal outcomes.

Authors:  Yun Hu; Yi-Ling Ding; Ling Yu
Journal:  Ther Clin Risk Manag       Date:  2014-05-23       Impact factor: 2.423

8.  Severe First Trimester Recurrent Intrahepatic Cholestasis of Pregnancy: A Case Report and Literature Review.

Authors:  Andrea G Hubschmann; Kelly M Orzechowski; Vincenzo Berghella
Journal:  AJP Rep       Date:  2015-10-21

9.  Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study.

Authors:  L B Manna; C Ovadia; A Lövgren-Sandblom; J Chambers; S Begum; P Seed; I Walker; L C Chappell; H-U Marschall; C Williamson
Journal:  BJOG       Date:  2019-09-26       Impact factor: 6.531

10.  Alanine aminotransferase as a predictor of adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy.

Authors:  Ali Ekiz; Basak Kaya; Muhittin Eftal Avci; Ibrahim Polat; Selin Dikmen; Gokhan Yildirim
Journal:  Pak J Med Sci       Date:  2016 Mar-Apr       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.